Optipharm.CO.LTD (153710) - Total Liabilities

Latest as of September 2025: ₩16.61 Billion KRW ≈ $11.26 Million USD

Based on the latest financial reports, Optipharm.CO.LTD (153710) has total liabilities worth ₩16.61 Billion KRW (≈ $11.26 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Optipharm.CO.LTD to assess how effectively this company generates cash.

Optipharm.CO.LTD - Total Liabilities Trend (2015–2024)

This chart illustrates how Optipharm.CO.LTD's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Optipharm.CO.LTD to evaluate the company's liquid asset resilience ratio.

Optipharm.CO.LTD Competitors by Total Liabilities

The table below lists competitors of Optipharm.CO.LTD ranked by their total liabilities.

Company	Country	Total Liabilities
Estrella Resources Ltd AU:ESR	Australia	AU$680.72K
Cassiar Gold Corp V:GLDC	Canada	CA$6.13 Million
Econpile Holdings Bhd KLSE:5253	Malaysia	RM247.59 Million
Balatacilar Balatacilik Sanayi ve Ticaret AS IS:BALAT	Turkey	TL21.04 Million
Ipopema Securities SA WAR:IPE	Poland	zł700.09 Million
Futuretech II Acquisition Corp NASDAQ:FTII	USA	$10.38 Million
Shree Rama Newsprint Limited NSE:RAMANEWS	India	Rs5.38 Billion
BRAIN Biotech AG XETRA:BNN	Germany	€64.50 Million

Liability Composition Analysis (2015–2024)

This chart breaks down Optipharm.CO.LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Optipharm.CO.LTD.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.29	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.65	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.39	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Optipharm.CO.LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Optipharm.CO.LTD (2015–2024)

The table below shows the annual total liabilities of Optipharm.CO.LTD from 2015 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩15.98 Billion ≈ $10.83 Million	+13.11%
2023-12-31	₩14.13 Billion ≈ $9.58 Million	+16.10%
2022-12-31	₩12.17 Billion ≈ $8.25 Million	+19.17%
2021-12-31	₩10.21 Billion ≈ $6.92 Million	+35.43%
2020-12-31	₩7.54 Billion ≈ $5.11 Million	+23.42%
2019-12-31	₩6.11 Billion ≈ $4.14 Million	-15.07%
2018-12-31	₩7.20 Billion ≈ $4.88 Million	+1.97%
2017-12-31	₩7.06 Billion ≈ $4.78 Million	-0.27%
2016-12-31	₩7.08 Billion ≈ $4.79 Million	-46.06%
2015-12-31	₩13.12 Billion ≈ $8.89 Million	--

About Optipharm.CO.LTD

KQ:153710 Korea Diagnostics & Research

Market Cap

$51.60 Million

₩76.14 Billion KRW

Market Cap Rank

#21761 Global

#1417 in Korea

Share Price

₩5190.00

Change (1 day)

-0.95%

52-Week Range

₩4850.00 - ₩6200.00

All Time High

₩28900.00